Following a patient death linked to their experimental ALLO-647 treatment, Allogene Therapeutics has made a significant strategic decision to proceed with the standard fludarabine and cyclophosphamide (FC) lymphodepletion regimen in its ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma.
Critical Safety Event Prompts Trial Modification
A Grade 5 adverse event (patient death) from hepatic failure on Day 54 post-infusion, which was thought to be caused by a disseminated adenovirus infection in the context of immunological suppression, led to the decision to close the FC plus ALLO-647 arm. The usage of ALLO-647, an anti-CD52 monoclonal antibody, was blamed for the incident, which was determined to be unconnected to cema-cel.
Read More: Gilead’s Lenacapavir for HIV Prevention Gets Positive CHMP Nod
The loss of a patient is always deeply saddening, and we extend our heartfelt condolences to the patient’s family,
This event, which prompted an early review of the trial data, compelled us to make a decisive choice – one that may ultimately help bring this potentially life-saving therapy to patients more quickly. The ability to administer cema-cel following standard FC lymphodepletion in an outpatient setting will simplify study treatment and has the potential to accelerate trial enrollment and streamline regulatory review, ultimately transforming care for patients.
David Chang
Strategic Shift Away from ALLO-647
Allogene has made a more extensive strategic shift as a result of this safety incident. According to the business, ALLO-647 is not included in any pipeline programs or open trials. Rather, Allogene is employing the exclusive Dagger® Platform Technology to develop its next-generation AlloCAR T product candidates, which is intended to reduce or even do away with the necessity of conventional lymphodepletion.
This incident is not the only instance of ALLO-647’s safety issues. Allogene admitted that severe viral infections were uncommon in their clinical studies, but when they did occur, they were linked to immunosuppression brought on in part by ALLO-647. Interestingly, throughout Allogene’s trials, no person receiving FC lymphodepletion has experienced adenoviral infection or hepatic failure.
Read More: AbbVie Enters Into the Obesity Drug Market With a License Agreement
ALPHA3 Trial Redesign and Timeline
The current standard of therapy, cema-cel following routine FC lymphodepletion, is being compared to observation in the ALPHA3 trial, which is now being conducted as a two-arm randomized study. The predetermined study conduct and statistical design are unaltered.
- In the US and Canada, more than 50 clinical sites have been activated.
- Both large academic institutions and community cancer centers are among the locations.
- The futility analysis is still slated for the first half of 2026.
- MRD (minimum residual disease) conversion rates will be compared in the analysis.
Market Opportunity and Treatment Rationale
A major unmet medical need in the treatment of large B-cell lymphoma is addressed by the trial. In the US, the EU, and the UK, more than 60,000 patients are anticipated to receive LBCL treatment per year. Although the majority of patients react well to first-line R-CHOP or other chemoimmunotherapy, about 30% of those who do so will relapse and need further care.
Following first-line treatment, the current standard of care has been to “watch and wait” to see if the disease recurs. Cema-cel, which could become the conventional “7th cycle” of frontline treatment, is positioned by the ALPHA3 research as a one-time, “off-the-shelf” treatment that can be given right away upon the identification of MRD after six cycles of R-CHOP or other chemoimmunotherapy.
Last Modified:
Graduated from the University of Kerala'20 with B.Sc. Botany & Biotechnology. Post-graduation in Biotechnology from the University of Kerala'22. Internship experience in Cancer Research.
